Publication | Closed Access

An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer

OncologyMedicinePathologySecond-line TherapyImmune Checkpoint InhibitorPemetrexed Versus PemetrexedCancer TreatmentEribulin Mesylate AdministeredPharmacologyRadiation OncologyLung Cancer